Vesicular stomatitis virus: an exciting new therapeutic oncolytic virus candidate for cancer or just another chapter from Field's Virology?
Selected mutant strains of vesicular stomatitis virus (VSV) are described that are unable to combat endogenous IFN-beta signaling within infected normal cells and as a result are dramatically more selective for productive growth in tumor cells having a defective antiviral response. The VSV mutants may have the potential to be used clinically as a systemic oncolytic agent for the treatment of distal and metastatic cancers.
Cancer Research, Cerus Corporation, 2411 Stanwell Drive, Concord, CA 94520, USA.
Martin A
MA
Giedlin
David N
DN
Cook
Thomas W
TW
Dubensky
D000818:Animals; D006801:Humans; D016899:Interferon-beta / Q000037:antagonists & inhibitors / Q000378:metabolism*; D009154:Mutation; D009369:Neoplasms / Q000628:therapy / Q000821:virology; D012327:RNA Virus Infections / Q000628:therapy* / Q000821:virology; D015398:Signal Transduction; D014721:Vesicular stomatitis Indiana virus / Q000502:physiology*; D014780:Viruses / Q000378:metabolism*
D016899:Interferon-beta